According to the practice guideline from Europe proposed in 2016 pharmacotherapies should be considered for NASH patients with fibrosis stage 2 or higher and with early stage fibrosis with high risk of fibrosis progression older age diabetes metabolic syndrome increased ALT and high necroinflammatory activity .

Reversal of steatohepatitis with at least no worsening of fibrosis has been considered as a primary endpoint of clinical trials.Although hepatic fibrosis is the most critical determinant of all-cause or liver-related mortality in NASH it remains to be solved whether improvement in hepatic fibrosis canlead to prevention of liver-related mortality in NASH patients.

Takeda et al.

Akuta et al.

They should also confirm that they have full control of all primary data and that they agree to allow the journal to review their data if requested.Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License   which permits unrestricted use distribution and reproduction in any medium provided you give appropriate credit to the original authors and the source provide a link to the Creative Commons license and indicate if changes were made.ReferencesYounossi ZM Koenig AB Abdelatif D et al.

20166473-84.Eguchi Y Hyogo H Ono M et al JSG-NAFLD.

2009201247586-95.Goldberg D Ditah IC Saeian K et al.

20171521090-9.Nakamura J Kamiya H Haneda M et al.

20178397-410.Chalasani N Younossi Z Lavine JE et al American Gas- troenterological Association American Association for the Study of Liver Diseases American College of Gastroenterology.

2016641388-402.Chalasani N Younossi Z Lavine JE et al.

